Navigation Links
Cancer risk found for long-term hormone therapy
Date:8/11/2010

Using postmenopausal hormone therapy for more than 15 years increases a woman's risk of developing breast cancer, particularly among leaner women according to research at the Keck School of Medicine of the University of Southern California (USC).

An analysis of the California Teachers Study focused on postmenopausal hormone therapy use among more than 55,000 women for nearly 10 years. The research was conducted by a team including first author Tanmai Saxena, an M.D. Ph.D student at the Keck School. The research was published today in Cancer Epidemiology, Biomarkers and Prevention, an American Association for Cancer Research journal.

Compared with women who never used postmenopausal hormone therapy, women who used estrogen therapy for more than 15 years were at a 19 percent increased risk of breast cancer. The risk was even more pronounced for women who used combined therapy with estrogen plus progestin for 15 or more years. These women had an increased risk of 83 percent, Saxena said.

"This study shows that there needs to be a personalized conversation with women about the risks of using postmenopausal hormone therapy," said Saxena. "Different women appear to have different risks from hormones."

Thinner women who go on hormone therapy also appear to be at higher risk, Saxena said.

The research revealed that body mass index (BMI) may be an indicator of breast cancer risk for women who use postmenopausal hormone therapy. Women with a BMI of 30 or less appear to be at increased risk of breast cancer from combined therapy, while women with a BMI of 30 or higher were at less risk. Women with a BMI of 25 or less were at the highest risk.

The purpose of the study was to elaborate on the Women's Health Initiative findings regarding the effects of postmenopausal hormone therapy on breast cancer risk. The 15-year WHI, conducted by the National Institutes of Health, was halted in 2002 after increased risks of cardiovascular disease and breast cancer were found among women who were taking combination therapy as part of the trial. This study looked at the risk associated with particular formulations of combination hormone therapy as well as the subtypes of breast cancer resulting.


'/>"/>

Contact: Leslie Ridgeway
leslie.ridgeway@usc.edu
323-442-2823
University of Southern California
Source:Eurekalert

Related biology news :

1. Breast cancer treatment resistance linked to signaling pathway
2. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
3. The dietary supplement genistein can undermine breast cancer treatment
4. Saliva proteins could help detection of oral cancer
5. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
6. Breakthrough optical technology to assess colon cancer risk, accuracy
7. Breast cancer cells recycle to escape death by hormonal therapy
8. Nanodiamond drug device could transform cancer treatment
9. Second lumpectomy for breast cancer reduces survival rates
10. Study looks at psychological impact of gene test for breast cancer
11. SNM releases new fact sheet on breast cancer and molecular imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
(Date:6/23/2016)... Connecticut (PRWEB) , ... June 23, 2016 , ... ... introduce a new line of intelligent tools designed, tuned and optimized exclusively for ... September 12–17 in Chicago. The result of a collaboration among several companies with ...
Breaking Biology Technology: